In conclusion, our study provides preliminary evidence for the combination of HAIC, lenvatinib, and PD-1 inhibitors in the treatment of advanced HCC, including in patients with heavy tumor burden and those who are refractory to TACE. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.